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Anaphylatoxin formation during hemodialysis: Comparison of new and
re-used dialyzers. Hemodialysis of 11 endstage renal failure patients
with new cuprophan hollow fiber dialyzers produced significant leuko-
penia as well as increased plasma levels of both C3a and C5a antigens
during the initial phases of the procedure. Formalin-fixed new dialyzers
produced quantitatively similar phenomena in eight of these same
patients. By contrast, hemodialysis with re-used dialyzers, that is
dialyzers exposed to blood prior to formalin sterilization, produced only
a 20 to 30% decline in peripheral blood leukocyte counts. Correspond-
ingly, C3a antigen formation within re-used dialyzers was only 20% of
that observed in new dialyzers. Re-used dialyzers also differed signifi-
cantly from either new or formalin-fixed new dialyzers in that C3b
antigen could be readily detected within them even after extensive
washing. These observations suggest that C3b deposition on the cellu-
losic membrane surface during first use markedly diminishes the
complement activating potential of cuprophan dialyzers when they are
subsequently re-used.
Formation d'anaphylatoxines pendant l'hémodialyse: Comparaison
entre les dialyseurs neufs et réutilisés. L'hémodialyse de 11 malades en
insuffisance rénale terminale avec des dialyseurs neufs a fibres capil-
laires en cuprophan a entrainé une leucopénie significative, ainsi qu'une
élévation des niveaux plasmatiques des antigènes C3a et C5a pendant
les phases initiales du traitement. Des dialyseurs neufs fixes a Ia
formaline ont entraIné des phénomènes quantitativement similaires
chez huit des mCmes malades. A l'opposé, l'hémodialyse avec des
dialyseurs réutilisés, c'est-à-dire des dialyseurs exposés a du sang avant
Ia stérilisation a Ia formaline, n'a produit qu'une diminution de seule-
ment 20 a 30% de Ia numeration des leucocytes sanguins périphériques.
En méme temps Ia formation d'antigenes C3a dans les dialyseurs
réutilisés n'était que de 20% de celle observée dans les dialyseurs neufs.
Les dialyseurs réutilisés étaient également significativement differents
des dialyseurs neufs ou fixes a Ia formaline en ce que l'antigene C3b
pouvait étre facilement détecte a l'intCrieur, méme aprés lavage exten-
sif. Ces observations suggerent que le dépôt de C3b a Ia surface de
membranes en cellulose pendant Ia premiere utilisation diminue de
facon marquee le potentiel d'activation du complement des dialyseurs
en cuprophan Iorsqu'ils sont ensuite réutilisés.
Cellulosic hollow fiber dialyzers have been demonstrated to
promote significant activation of the human complement cas-
cade that results in the production of both C3a and C5a
anaphylatoxins [1]. Furthermore, dialyzer-associated comple-
ment activation, as judged by C3a antigen formation, is corre-
lated temporally with hemodialysis leukopenia suggesting that a
Received for publication April 14, 1983
and in revised form May 31, 1983
© 1983 by the International Society of Nephrology
complement-derived mediator is responsible for the transient
pulmonary vascular leukosequestration observed in the dia-
lyzed patient [1—7]. Current evidence favors the hypothesis that
it is actually C5a anaphylatoxin, or its less active des Arg
derivative, that binds to specific receptors found on peripheral
blood granulocytes [8] and causes these cells to aggregate in or
become hyperadherent to the pulmonary vasculature [5—7]. The
proposal that dialyzer-associated complement activation, ana-
phylatoxin formation, and leukopenia represent an interrelated
series of phenomena is also supported by the observation that
dialyzers that do not activate complement, such as those
composed of polyacrylonitrile, also fail to provoke hemodialy-
sis leukopenia [1].
While new cuprophan' dialyzers consistently induce hemodi-
alysis leukopenia, many investigators have noted that re-use of
these same dialyzers after exposure to blood and formalin
sterilization tends to promote less hemodialysis-associated neu-
tropenia [9—12]. It has been suggested that this phenomenon
might be due to either the release of epinephrine [12] or a failure
of re-used dialyzers to activate complement [9]. To confirm this
latter hypothesis, we have used anaphylatoxin radio-
immunoassay techniques to quantitatively define and compare
the complement activating potential of new cuprophan dialyz-
ers, new dialyzers that have been exposed to formalin but not
blood, and re-used dialyzers.
Methods
Patients. Eleven patients, six females and five males, ranging
in age from 20 to 74 years, voluntarily participated in this study.
All patients were being treated at the University of California,
San Diego, hemodialysis unit and had been on treatment for at
least 1 month, with the mean duration of dialysis being 2 years.
None of these patients had intercurrent acute illness nor were
they taking corticosteroid during the study period. The investi-
gational protocol was approved by the Human Subjects Com-
mittee of the University of California, San Diego, and informed
'The term "cuprophan" is employed to broadly denote all cellulosic
membranes manufactured by the cupramonium process. A more formal
generic term for these membranes is "cupramonium rayon." An
alternative synonym, "Cuprophan," is the trade name applied to
cupramonium rayon by the manufacturer, Membrana AG (formerly
Enka AG). All of the dialyzers utilized in the present study were
fabricated from Cuprophan membranes.
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consent was obtained from all subjects.
Re-used dialyzers. The hemodialysis unit of the University of
California, San Diego, Medical Center has practiced dialyzer
re-use for the past 8 years. Each dialyzer is retired after the
sixth use, or earlier for any of the following reasons: (1) fiber
bundle volume is less than 80% of baseline, (2) a febrile reaction
occurs during dialysis, (3) blood leakage from the dialyzer
occurs, or (4) the dialyzer's external casing is not intact.
Dialyzer re-use is not employed in patients suspected of having
an active systemic infection, for example, chronic hepatitis.
After each use, the dialyzer was processed according to the
following protocol. The blood compartment was first rinsed
with heparin-free water which had been purified by reverse
osmosis (approximately 2000 ml at 20 PSI). Following this,
"reverse" ultrafiltration (casing to blood path) was carried out
with similarly purified water (>1000 ml). Fiber bundle volume
was then determined and dialyzers with volumes less than 80%
of baseline were discarded. The dialyzer was then stored in
0.75% formaldehyde (2% formalin) which was used to fill both
the blood and dialysate compartments. Immediately prior to the
next use, formalin was removed both by dialysis and washing of
the blood path with sterile normal saline (approximately 500
ml). Finally, the dialyzer effluent was analyzed with Schiff's
reagent to insure that residual formalin content was < 10 ppm.
Formalin-fixed new dialyzers. In addition to re-used dialyz-
ers, that is dialyzers first exposed to blood and then stored in
formalin, formalin-fixed new dialyzers were also prepared.
These units, designated "new + CH2O," were prepared and
handled exactly as described above except they were not
exposed to blood or plasma proteins at any time prior to
formalin sterilization.
Hemodia/ysis procedure. A previously unused dialyzer was
employed to initiate the study. During five subsequent dialysis
sessions this same dialyzer was re-used after processing as
noted above. The study concluded with the use of a second new
dialyzer. Nine patients re-used the same dialyzer five times
before a new one was employed. The two other patients re-used
their dialyzers three or four times, respectively, re-use being
discontinued because of low fiber bundle volumes.
All patients were dialyzed with cuprophan hollow fiber
dialyzers. Three utilized TE 10 (Terumo, Japan, surface area =
1.0 M2); seven utilized TE 15 (Terumo, Japan, surface area =
1.5 M2); and one utilized CF 1211 (Travenol Laboratories, Inc.,
Morton Grove, Illinois, surface area = 0.8 M2). The blood flow
rate was maintained at 260 8 mI/mm (mean SEM) from an
internal arteriovenous fistula and dialysate flow rate was main-
tained at 500 ml/min in a single pass mode.
In a separate series of dialysis procedures, eight of the 11
patients were dialyzed once with formalin-fixed new dialyzers.
Both blood and dialysate flow rates were comparable to those
stated above.
Sample collection. During each dialysis session, 3 ml of
whole blood were initially obtained from the patient's arteriove-
nous fistula (pre-dialysis, time 0). Two additional blood samples
were drawn from the venous (outflow) line of the dialyzer 10
and 15 mm after the onset of dialysis. Previous studies have
indicated that these time points provided reliable measurements
of both hemodialysis leukopenia and anaphylatoxin formation
[1]. The blood samples were immediately placed into test tubes
containing liquid disodium ethylenediamine tetracetate (final
concentration, 20 mM) to prevent further complement
activation.
Anaphy/atoxin radioimmunoassay procedures. Blood sam-
ples were analyzed within 1 hr after being drawn. Total leuko-
cyte (WBC) counts were obtained with a cell counter (Coulter
Model ZF), Venous plasma concentrations of the complement-
derived anaphylatoxins C3a and C5a were determined by
previously published radioimmunoassay procedures [13, 141.
Quantitation of plasma C3a and C5a antigens were obtained
from duplicate determinations by means of a standard curve
(the amount of radio-iodinated ligand bound versus the loga-
rithm of the concentration of the ligand) whose correlation
coefficient was greater than 0.98,
Student's unpaired t test was used for all statistical compari-
sons. A P value of less than or equal to 0.05 was considered to
be significant.
Det"-"" nf dialyzer-associated C3b antigen. Rabbit anti-
human C3 antiserum was cained by repeated immunization of
New Zealand white rabbits with human C3 prepared by the
method of Tack and Prahl [151. Rabbit anti-human C3b immu-
noglobulins were then purified from this antiserum by affinity
chromatography on a C3b Sepharose 4B column (5 ml bed
volume). These specific immunoglobulins (100 g) were radio-
iodinated with 1 mCi Na'251 by a solid phase lactoperoxidase-
glucose oxidase method (BioRad Enzymobeads, BioRad Tech-
nical Bulletin 79-03 18, BioRad Laboratories, Richmond, Cali-
fornia) and free 125j removed by gel filtration on a 5 ml column
of Bio Gel P4 equilibrated with phosphate-buffered saline, pH
7.4 (PBS) which contained 0.5% gelatin as a carrier. The
specific activity of the '251-anti-C3b thus prepared was 8.5
Ci/g and the radioiodinated antibody remained functional,
l'5that is, nearly 70% of the - I-anti-C3b rebound to C3b-
Sepharose 4B.
The following procedures were employed to detect C3b
antigen remaining firmly associated with cuprophan dialyzers.
The dialysate compartment of either new, formalin-fixed new,
or re-used dialyzers was first rinsed extensively with water.
Following this, the blood compartment of the dialyzer was
rinsed with 2000 ml of water and 250 ml of normal saline, both at
a flow rate of 280 ml/min. When these rinsing procedures were
completed, the dialyzer, containing approximately 30 to 40 ml
of residual saline in the blood compartment was connected to a
reservoir containing 1 g of '251-anti-C3b (approximately,
30,000 cpm/ml) in 250 ml PBS supplemented with 0.5% bovine
serum albumin as a carrier protein. After sampling (initial), this
solution was recycled continuously through the blood compart-
ment of the dialyzer for 10 mm at a flow rate of 280 mI/mm.
Following this, the volume and specific activity of the recov-
ered '251-anti-C3b solution was determined (final). The amount
of radioiodinated anti-C3b bound by each type of dialyzer was
then calculated from the following formula:
Percent '251-Anti-C3b Bound =
I — Final volume (ml) x cpm/ml 100Initial volume (ml) x cpm/ml
Results
Comparison of new and formalin-fixed new dia/yzers. Previ-
ous studies demonstrated that the complement-activating ca-
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Fig. 1. Hemodialysis-associated leukopenia observed with different
types of cuprophan dialyzers. Patients were dialyzed with new (N = 11,
•), formalin-fixed new (N = 8, 0) or re-used dialyzers (first re-use, N
= 11, A; third re-use, N = 10, A) and their peripheral blood leukocyte
counts determined during the initial phases of hemodialysis. Each data
point represents the mean SEM of duplicate determinations in each
patient.
pacity of different types of hemodialyzers could be defined
accurately by measuring the hemodialysis-associated leukope-
nic response and quantitating the amount of anaphylatoxin
formation taking place in the dialyzer during the first 15 mm of
hemodialysis [1]. Therefore, in the present study, venous
(dialyzer outflow) blood samples obtained after 10 and 15 mm of
dialysis were analyzed and compared to those drawn prior to
dialysis.
Using these approaches, we compared new and formalin-
fixed new cuprophan hemodialyzers to determine if exposure of
the cellulosic membrane to formaldehyde alone would alter the
complement activating potential of this biopolymer. Prior to
hemodialysis, both groups of patients had similar peripheral
blood leukocyte counts. For patients dialyzed with new dialyz-
ers, the range of WBC counts was 3230 to 10,150 WBC/mm3
(mean SD, 5907 1866) and for those dialyzed with formalin-
fixed dialyzers the range of leukocyte counts was 2665 to 7200
WBC/mm3 (mean SD, 4461 1335). As shown in Figure 1,
utilization of either type of dialyzer in the extracorporeal circuit
during dialysis provoked a significant leukopenic response in
both groups of dialyzed patients. Comparison of both types of
dialyzers demonstrated no significant difference between either
the magnitude of this response or its temporal profile. Typical-
ly, each type of dialyzer caused a 70% reduction in the number
of circulating leukocytes with this nadir being observed 15 mm
after the onset of hemodialysis.
Similarly, both new and formalin-fixed new dialyzers were
equally capable of promoting complement activation. As shown
in Figure 2, soon after the onset of dialysis with either of these
dialyzers, significant quantities of C3a were observed in venous
Time on dialysis, rn/n
Fig. 2. Generation of C3a antigen during the initial phases of hemodial-
ysis. Patients dialyzed with either new (N = 11, •) or formalin-fixed
new (N = 8, 0) cuprophan dialyzers exhibit significant levels of C3a
antigen in their venous plasma. Dialyzer re-use, either one time (N =
11, A) or three times (N = 10, A), produces significantly less comple-
ment activation. Each data point represents the mean SEM of
duplicate determinations performed on plasma samples from each
individual.
plasma. Again, there was no significant difference in either the
rate of formation or the quantity of this antigen in plasma when
these dialyzers were compared during the first 15 mm of
hemodialysis. These findings clearly demonstrate that formalin
by itself does not significantly alter the inherent complement
activating potential of cellulosic membranes.
Dialyzer re-use and complement activation. Re-used dialyz-
ers differ from formalin-fixed new dialyzers because they have
been exposed to blood prior to formalin sterilization. As a
result, the complement activating capacity of re-used dialyzers
also differs significantly from that of either new or formalin-
fixed new dialyzers.
As shown in Figure 1 and Table 1, when a re-used dialyzer is
employed in the extracorporeal circuit for the first time, the
patient's leukopenic response is reduced significantly (P <
0.001) when compared to that produced by a new dialyzer.
Additionally, the complement activating capacity of a re-used
dialyzer is significantly less than that of a new one. For
example, we note that after 15 mm of dialysis, the plasma levels
of both C3a (P < 0.001) and C5a (P < 0.01) antigens are only
about 20% of those observed in the outflow line of a new
dialyzer.
With repeated use, re-used dialyzers continue to demonstrate
enhanced biocompatibility. The patient's leukopenic response
remains modest during the next five dialysis procedures, but
promptly returns when a new dialyzer is introduced (Table 1).
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Table 1. Suppression of hemodialysis leukopenia and anaphylatoxin formation with dialyzer reusea
Parameter
.Time on
dialysis
Times cuprophan dialyzer re-used
0 0
measured mm (New) 1 2 3 4 5 (New)
Relative WBC 0 100 100 100 100 100 100 100
count, % 10
15
65.7 8.3
31.3 6.1
79.7 5.8
71.6 9.6
82.1 4.5
77.1 8.3
78.6 7.2
77.9 8.7
77.7 4.5
75.8 7.1
81.0 6.8
76.7 9.8
65.4 8.7
34.8 7.1
Plasma C3a, 0 452 73 398 69 359 57 221 55 271 52 304 46 350 54
nglml 10
15
4951 1182
5540 926
934 228
1005 314
1010 318
953 331
553 117
588 142
755 185
1166 410
1078 367
1136 420
3668 1013
4186 1156
Plasma C5a, 0 62 15 32 9 34 II 51 22 42 18 69 21 56 13
ng/ml 10
15
131 27
200 45
37 12
43 17
35 II
35 12
37 18
44 17
18 10
60 18
52 15
78 2!
110 22
158 40
Numbers of studies 11 11 11 10 10 9 Il
All data presented as mean sr; all values obtained at IS mm during re-use show a significant difference from the corresponding values
obtained with new dialyzers (P  0.05).
Table 2. Binding of 251-ANTI-C3b to dialyzers
Dialyzer N
Percent '25l-anti-C3b
bound (mean SD)
New cuprophan 3 23.6 0.7
Formalin-fixed
New cuprophan 3 23.7 1.1
Re-used cuprophan 3 72.5 I 4a
C3b-Sepharose 4B
(Positive control) 3 67.9 0.2
a p < 0.001 versus new or formalin-fixed new cuprophan.
Similarly, anaphylatoxin formation within the re-used dialyzers
remains significantly depressed each time these dialyzers are
used. Minimal C3a formation is observed during the third time a
re-used dialyzer is employed (fourth use in the series beginning
with a new dialyzer), suggesting that the complement-activating
capacity of the cellulosic membrane may be ablated gradually
with repeated blood exposure. That failure to activate comple-
ment is a specific property of re-used dialyzers is demonstrated
clearly by the fact that all of these patients display elevated
plasma levels of C3a antigen when dialyzed with new cupro-
phan dialyzers at the end of the re-use schedule.
C3b deposition in re-used dialyzers. Our clinical findings
suggested that some component(s) of blood, rather than formal-
in alone, might be responsible for the reduced complement-
activating capacity of re-used dialyzers. Because C3(b) is not
only an obligatory component of the alternative pathway of
complement but also becomes covalently bound to its activating
site during alternative pathway activation events, we suspected
that re-used dialyzer membranes might be coated with this
protein. To test this hypothesis, we employed radioiodinated
anti-C3b as a tracer to detect membrane bound C3b antigen on
re-used dialyzers. As shown in Table 2, approximately 23% of
the offered '251-anti-C3b was not recovered after extensive
exposure to either new or formalin-fixed new cuprophan dialyz-
ers. Modest binding of the tracer to these dialyzers is compati-
ble with dilution of the antibody solution by the saline prime
remaining in the dialyzer as well as minimal nonspecific binding
of this dilute immunoglobulin solution. By contrast, re-used
dialyzers, like C3b-Sepharose 4B used as a positive control,
removed all of the functional '251-anti-C3b from the solution.
These findings are compatible with the hypothesis that re-used
dialyzers differ markedly from either new or formalin-fixed new
dialyzers because they have significant quantities of C3b anti-
gen firmly attached to their membrane surface.
Discussion
We have observed that new cuprophan dialyzers provoke a
considerably greater degree of hemodialysis-associated leuko-
penia than re-used dialyzers which agrees with previous reports
[9—121. By using anaphylatoxin radioimmunoassay techniques
to quantitate the amount of complement activation taking place
in each type of dialyzer, we have also been able to demonstrate
that re-used dialyzers activate complement very little when
compared to new ones. Additionally, the enhanced biocompati-
bility of re-used cuprophan dialyzers may result, at least in part,
from the fact that complement activating sites on the cellulosic
membrane are masked effectively by C3b or a C3b-derived
fragment, such as C3d, that becomes firmly associated with
these sites when the new dialyzer is used initially. Taken
together, our data are most compatible with the proposal that
initial exposure of the cellulosic membrane to blood not only
promotes complement activation and leukopenia, but also de-
position of C3b on the membrane surface. As a result, comple-
ment activating sites on the biopolymer are blocked effectively.
Correspondingly, re-use of these C3b-coated dialyzers is asso-
ciated with only modest complement activation and hemodialy-
sis leukopenia,
Our current investigations demonstrate that each time a new
dialyzer is utilized in the extracorporeal circuit, significant
leukopenia and anaphylatoxin generation takes place. These
findings clearly support the concept that the phenomena ob-
served with dialyzer re-use do not result from an acquired
alteration of the patient's ability to activate complement, but
instead reflect an inherent property of the formalin sterilized re-
used dialyzer itself.
Other investigators have focused on the putative role of
formalin as causative of the phenomena associated with dialyz-
er re-use [161. Our findings do not support their hypothesis that
residual formalin in the re-used dialyzer functions to inactivate
C5a (des Arg). Our own control experiments clearly demon-
strate that formalin-fixed new dialyzers fully retain the capacity
to both activate complement and produce a functionally active
C5a molecule that is capable of inducing a typical leukopenic
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response. The fact that ablation of both the leukopenic response
and complement activation results only after a cuprophan
dialyzer is exposed to blood and then formalin sterilized strong-
ly supports the idea that one or more constituents of blood,
rather than formalin alone, is required to produce the phenome-
na that are clinically manifest during dialyzer re-use.
Although formaldehyde by itself may not inhibit complement
activation, this fixative may enhance the nonspecific attach-
ment of plasma proteins to the dialyzer membrane surface. In
this way, formalin sterilization may facilitate the coating of
cellulosic membranes with fibrin [17] or even significant quanti-
ties of albumin. However, albumin at least, can be eluted from
re-used dialyzers by vigorous washing (unpublished observa-
tions). By contrast, C3b antigen remains firmly associated with
re-used dialyzers. This unique property may result from cross-
linking and formaldehyde fixation or, what seems more likely,
C3b becomes covalently attached to the activating sites on the
cellulosic membrane via a transesterification reaction with
internal thiolester bond found at this molecule's active site [18—
20]. Additionally, our current findings suggest that re-use of
cuprophan dialyzers not only affords significant economic bene-
fit, but may also provide a useful means of limiting anaphyla-
toxin formation and resultant hemodialysis leukopenia. To the
extent that these phenomena account for clinically manifest
pulmonary dysfunction [7, 21] and/or untoward signs or symp-
toms during hemodialysis, re-used dialyzers may be preferred
when compared with new ones.
In summary, our data favors the previously proposed concept
that minimal hemodialysis leukopenia is associated with dialyz-
er re-use because re-used dialyzers demonstrate a relatively
impaired ability to activate complement [9]. These phenomena
most likely result from the fact that the complement-activating
sites of the cellulosic membrane become masked by C3b and/or
a C3b-derived product(s) that is deposited on the membrane
surface during first use and remains firmly bound to these sites.
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